Nuvectis Pharma sees biotech fund interest as Rimini Street CEO sells stock

Institutional filings reveal significant investment activity in Nuvectis Pharma (NASDAQ: NVCT). Healthcare-focused funds have increased their positions following the company’s expansion into immunology with its late-stage Complement Factor B inhibitor, NXP100. Notable investors include Soleus Capital Management, which holds a stake exceeding 5 percent, and Tang Capital Management, which holds 1,550,000 shares. Perceptive Advisors also established a position of 1,000,000 shares.

In separate news, Rimini Street, Inc. CEO Seth Ravin sold 191,702 shares of company stock at an average price of $5.18, totaling approximately $993,016. This transaction represents a 1.83% decrease in his direct holdings, leaving him with 10,299,607 shares valued at over $53 million. Recent institutional activity for Rimini Street includes new positions from Conifer Management L.L.C. and BlackRock Inc.